CIMO vs CRL
Chimera Investment Corporation (CIMO) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
Chimera Investment Corporation (CIMO) common stock listed on US.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
CIMO does not have a complete income-statement cache yet.
Latest reported CRL revenue for 2024-12-28 was $4.05B. Net income was $25.3M. Revenue was down 1.9% from 2023-12-30 to 2024-12-28. CRL currently screens at market cap $7.78B.
CIMO currently screens at market cap $0. CRL currently screens at market cap $7.78B.
Not investment advice. Open the CIMO and CRL stock pages for the full models.
Not investment advice.